The Future of Lexapro Industry

Overview:

Although Lexapro is an effective and widely used depression medication, it does have some side effects. Most of these side effects occur during the first two weeks of treatment and will subside as a body adjusts to the drug. Taking Lexapro is likely to create drowsiness. It is best to deal with this side effect at night or in the morning, when the patients are less likely to be distracted. It is advisable to discuss this side effect with a healthcare provider, particularly if it is causing patients to sleep less than they expected. 

To Get Complete Industry Insights, Grab Sample PDF Copy Here: https://bit.ly/3ArxdwI

Market Drivers:

The prevalence of fatal diseases such as obsessive-compulsive disorder, major depressive disorder, panic disorder and generalized anxiety disorder is increasing around the globe, which in turn is expected to propel growth of the global Lexapro market over the forecast period. As per the data of National Institutes of Health (NIH), approximately 21.0 million adults in the United States suffered at least one major depressive episode in the 2020, which is 8.4% of all the adults in the U.S.

Moreover, increasing approvals for antidepressant drugs and growing old age populations is also expected to augment growth of the global Lexapro market over the forecast period. 

Market Restraints:

Adverse side effects of such drugs, such as constipation, dizziness, and headache among others is anticipated to hinder growth of the global Lexapro market over the forecast period. 

Regional Analysis:

Among regions, Europe is anticipated to witness strong growth in the global Lexapro market over the forecast period. This growth can be attributed to increasing awareness regarding therapies for mental disorders, growing prevalence and increase in disposable incomes in the region. 

Furthermore, Asia Pacific is also anticipated to witness substantial growth in the global Lexapro market over the forecast period. This is due to increase in sales of antidepressant drugs and rise in prevalence of depressive syndrome in younger population across the region.

Key Players:

Major players active in the global Lexapro market are Macleods Pharmaceuticals, Lundbeck, Accord Healthcare, Amneal Pharmaceuticals, Aurobindo Pharma, Forest Laboratories, Hetero Drugs, TEVA, Hikma Pharmaceuticals, Mylan, Novartis, Silarx Pharmacueticals, Lupin, and Apotex among others.

In March 2022, Sun Pharma entered into patent licensing agreement with Lindbeck, Danish-drugmaker, for marketing and distributing its own form of antidepressant medication in India.